In order to understand what brings value to patients, you have to talk and listen to them, and you’ve got to do that in an intentional, thought through way, explained James Hamrick, MD, senior medical director at Flatiron Health.
In order to understand what brings value to patients, you have to talk and listen to them, and you’ve got to do that in an intentional, thought through way, explained James Hamrick, MD, senior medical director at Flatiron Health.
Transcript
What are some best practices for understanding what constitutes value for patients?
The first best practice to understand what brings value to patients is to talk to patients and listen to patients, and you’ve got to do that in an intentional, thought through way, because if you just try to work with your own assumptions, you’re going to be wrong a lot of the time. I go back to this idea of meeting patients where they are and making sure you design products that work within what they’re doing already in their life instead of requiring a whole lot of extra energy to access some sort of technology tool.
And I think in addition, we’ve recognized more and more that cancer care is very much a team sport. I see a lot of the practices that we work with build out things beyond just the traditional physician and nurse practitioner. We’ve talked to one practice that actually has group visits across the whole team. So, when a patient comes in and is going to begin treatment, they have an opportunity in a group setting to meet not only their physician but the infusion nurse who’s going to do their chemotherapy, the financial counselor who’s going to make sure they’re going to get their treatment without going bankrupt, the support teams that are going to be contacting them at multiple points along their journey to help them.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More